Clinical Roundup Cells in tumor microenvironment play critical role in effectiveness of rapalogs June 14, 2024Vol.50 No.24
Clinical Roundup Cosylab, Mayo Clinic collaborate to advance radiation therapy, support the first carbon ion treatment facility in the U.S. June 14, 2024Vol.50 No.24
Clinical Roundup MD Anderson, Sibylla Biotech collaborate to develop small-molecule protein degraders June 14, 2024Vol.50 No.24
Clinical Roundup Atlantic Health System, Mevion collaborate to bring proton therapy technology to Carol G. Simon Cancer Center June 14, 2024Vol.50 No.24
Drugs & Targets FDA approves Breyanzi for relapsed or refractory mantle cell lymphoma June 14, 2024Vol.50 No.24
Drugs & Targets FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors June 14, 2024Vol.50 No.24
Most cancer centers provide paltry resources for meeting NCI’s CCSG mandate to enhance diversity, study shows June 07, 2024Vol.50 No.23By Matthew Bin Han Ong
Conversation with The Cancer Letter Fred Hutch’s Christopher Li: Cancer centers should commit more resources to meet NCI’s Plan to Enhance Diversity requirements June 07, 2024Vol.50 No.23By Matthew Bin Han Ong
Indefinite course of osimertinib dramatically improves PFS in stage 3 EGFR-mutated NSCLC June 07, 2024Vol.50 No.23By Jacquelyn Cobb and McKenzie Prillaman
Trials & Tribulations Paired tumor-germline testing can enhance patient care—with guidance from genetics specialists June 07, 2024Vol.50 No.23By Rebecca Sutphen
